Pemvidutide Demonstrates Significant Metabolic Improvements in Patients with MASH in New 48‑Week IMPACT Phase 2b Data Presented at EASL 2026
Go back to Pemvidutide Demonstrates Significant Metabolic Improvements in Patients with MASH in New 48‑Week IMPACT Phase 2b Data Presented at EASL 2026| iShares Diversified Alternatives Trust (NASDAQ: ALT) | Delayed: 2.93 +0.23 (8.52%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $2.70 | 52 Week High | $54.24 | |||
| Open | $2.84 | 52 Week Low | $48.35 | |||
| Day High | $3.05 | P/E | N/A | |||
| Day Low | $2.83 | EPS | $0.00 | |||
| Volume | 5,771,010 | |||||
